Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Mirum Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Mirum Pharmaceuticals, Inc.

MIRM

Mirum Pharmaceuticals, Inc.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases, particularly cholestatic liver and bile acid disorders. Its core products include LIVMARLI, CHOLBAM, and CHENODAL, targeting conditions like Alagille syndrome, PFIC, and CTX. The company leverages proprietary drug candidates, licensing agreements, and strategic acquisitions to address high unmet medical needs in niche markets worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Mirum Pharmaceuticals, Inc.

1
1
Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals Reports 43% Increase in Net Product Sales, $790.2 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals Reports Revenue Growth to $521.3 Million and Strategic Developments in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals Reports $2.9 Million Net Income in Q3 2025, Up from Loss in 2024

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals Reports 64% Revenue Growth to $127.8 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals Reports $111.6 Million Revenue in Q1 2025, Improved Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals Reports Significant Revenue Growth and Strategic Acquisitions in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments